Patient characteristics (thrombolytic treatment)
| Thrombus location | Estimated thrombus age | Thrombolytic agent | Dose administered | Duration of treatment | Short-term outcome |
|---|---|---|---|---|---|
| Bilateral RVT | 1 day | SK | 24000 U/kg/day | 4 days | Complete patency |
| Unilateral RVT | 6 days | SK** | 24000 U/kg/day | 1 day | Complete patency |
| Unilateral RVT/inferior caval vein | 2 days | t-PA | 1.2 mg/kg/day | 1 day | Complete patency |
| Unilateral RVT/inferior caval vein | ? | t-PA | 1.7 mg/kg/day | 10 days | Complete patency |
| Inferior caval vein/superior caval vein2-150 | ? | UK† ‡ | 2000 U/kg/hour | 14 days | Failure |
| Superior caval vein2-150 | 1 day | t-PA | 0.5 mg single dose | 30 minutes | Complete patency |
| Bilateral femoral veins | 3 days | t-PA†† | 3 mg/kg/day | 7 days | Patient patency |
SK: streptokinase; t-PA: recombinant tissue type plasminogen activator; UK: urokinase.
↵2-150 Associated with central line; **mucosal bleeding; †hyperfibrinolytic state; ‡ cross-over from t-PA; †† cross-over from SK.